Details of the Drug

General Information of Drug (ID: DM70BU5)

Drug Name
Thalidomide
Synonyms
Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Approved [1], [2]
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 258.23
Topological Polar Surface Area (xlogp) 0.3
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.4 mL/min/kg [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.7 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 22.12781 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.4% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.95 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0525 mg/mL [3]
Chemical Identifiers
Formula
C13H10N2O4
IUPAC Name
2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Canonical SMILES
C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
InChI
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
InChIKey
UEJJHQNACJXSKW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5426
ChEBI ID
CHEBI:74947
CAS Number
50-35-1
DrugBank ID
DB01041
TTD ID
D0U7GK
VARIDT ID
DR00461
INTEDE ID
DR1572
ACDINA ID
D00669

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Inhibitor [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [9]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [8]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [7]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Multiple myeloma
ICD Disease Classification 2A83
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.51E-01 0.05 0.27
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 1.79E-01 9.66E-02 1.48E+00
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 2.12E-01 6.84E-02 4.60E-01
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 5.68E-01 6.40E-02 1.83E-01
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 1.09E-02 -3.26E-01 -1.59E+00
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.14E-01 7.49E-02 1.11E+00
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.03E-01 -2.08E-03 -9.42E-03
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 8.28E-01 -5.54E-02 -4.08E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 2.35E-02 7.82E-02 4.89E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 2.76E-01 8.14E-02 9.84E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 8.60E-01 1.59E-02 5.91E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.16E-01 4.53E-02 3.54E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 2.06E-01 -1.87E-01 -6.20E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 6.32E-02 1.30E-01 7.89E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 5.49E-01 5.15E-02 1.92E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.31E-01 2.00E-02 1.82E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.00E-01 4.21E-02 3.26E-01
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 2.46E-01 7.05E-01 9.44E-01
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 8.19E-01 -1.40E-02 -9.21E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Thalidomide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Carfilzomib DM48K0X Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Carfilzomib. Multiple myeloma [2A83] [80]
Panobinostat DM58WKG Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Panobinostat. Multiple myeloma [2A83] [81]
Elotuzumab DMEYHG9 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Elotuzumab. Multiple myeloma [2A83] [80]
Melphalan DMOLNHF Major Additive thrombogenic effects by the combination of Thalidomide and Melphalan. Multiple myeloma [2A83] [82]
Coadministration of a Drug Treating the Disease Different from Thalidomide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Ivosidenib. Acute myeloid leukaemia [2A60] [81]
Midostaurin DMI6E0R Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Midostaurin. Acute myeloid leukaemia [2A60] [81]
Idarubicin DMM0XGL Major Additive thrombogenic effects by the combination of Thalidomide and Idarubicin. Acute myeloid leukaemia [2A60] [82]
Arn-509 DMT81LZ Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Arn-509. Acute myeloid leukaemia [2A60] [81]
Gilteritinib DMWQ4MZ Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Gilteritinib. Acute myeloid leukaemia [2A60] [81]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Thalidomide and Oliceridine. Acute pain [MG31] [83]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Thalidomide and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [84]
Ivabradine DM0L594 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Ivabradine. Angina pectoris [BA40] [81]
Bepridil DM0RKS4 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Bepridil. Angina pectoris [BA40] [81]
Dronedarone DMA8FS5 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Dronedarone. Angina pectoris [BA40] [81]
Nifedipine DMSVOZT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Nifedipine. Angina pectoris [BA40] [81]
Bedaquiline DM3906J Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [81]
Chlormezanone DMTWUXR Moderate Additive CNS depression effects by the combination of Thalidomide and Chlormezanone. Anxiety disorder [6B00-6B0Z] [84]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Cilostazol. Arterial occlusive disease [BD40] [81]
Posaconazole DMUL5EW Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Posaconazole. Aspergillosis [1F20] [81]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Thalidomide and Roflumilast. Asthma [CA23] [83]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [81]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Thalidomide and Desipramine. Attention deficit hyperactivity disorder [6A05] [85]
Ofloxacin DM0VQN3 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Ofloxacin. Bacterial infection [1A00-1C4Z] [81]
Clarithromycin DM4M1SG Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Clarithromycin. Bacterial infection [1A00-1C4Z] [81]
Sparfloxacin DMB4HCT Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [81]
Gemifloxacin DMHT34O Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [81]
Norfloxacin DMIZ6W2 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Norfloxacin. Bacterial infection [1A00-1C4Z] [81]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levofloxacin. Bacterial infection [1A00-1C4Z] [81]
Retigabine DMGNYIH Moderate Additive CNS depression effects by the combination of Thalidomide and Retigabine. Behcet disease [4A62] [83]
Cariprazine DMJYDVK Moderate Additive CNS depression effects by the combination of Thalidomide and Cariprazine. Bipolar disorder [6A60] [85]
Lomustine DMMWSUL Major Additive thrombogenic effects by the combination of Thalidomide and Lomustine. Brain cancer [2A00] [82]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Eribulin. Breast cancer [2C60-2C6Y] [81]
Ixabepilone DM2OZ3G Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Ixabepilone. Breast cancer [2C60-2C6Y] [80]
Thiotepa DMIZKOP Major Additive thrombogenic effects by the combination of Thalidomide and Thiotepa. Breast cancer [2C60-2C6Y] [82]
Anastrozole DMNP60F Major Additive thrombogenic effects by the combination of Thalidomide and Anastrozole. Breast cancer [2C60-2C6Y] [82]
Cabazitaxel DMPAZHC Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Cabazitaxel. Breast cancer [2C60-2C6Y] [80]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [80]
Atorvastatin DMF28YC Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [80]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [81]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Thalidomide and Dihydrocodeine. Chronic pain [MG30] [84]
Levetiracetam DMTGDN8 Moderate Additive CNS depression effects by the combination of Thalidomide and Levetiracetam. Chronic pain [MG30] [85]
Necitumumab DMKOJSN Major Additive thrombogenic effects by the combination of Thalidomide and Necitumumab. Colorectal cancer [2B91] [86]
Capecitabine DMTS85L Major Additive thrombogenic effects by the combination of Thalidomide and Capecitabine. Colorectal cancer [2B91] [82]
Halothane DM80OZ5 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Halothane. Corneal disease [9A76-9A78] [81]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Sevoflurane. Corneal disease [9A76-9A78] [81]
Ketamine DMT5HA4 Moderate Additive CNS depression effects by the combination of Thalidomide and Ketamine. Corneal disease [9A76-9A78] [85]
Probucol DMVZQ2M Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Probucol. Coronary atherosclerosis [BA80] [81]
Chlophedianol DMXGJEI Moderate Additive CNS depression effects by the combination of Thalidomide and Chlophedianol. Cough [MD12] [84]
Pasireotide DMHM7JS Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pasireotide. Cushing syndrome [5A70] [81]
Osilodrostat DMIJC9X Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Osilodrostat. Cushing syndrome [5A70] [81]
Sertraline DM0FB1J Moderate Additive CNS depression effects by the combination of Thalidomide and Sertraline. Depression [6A70-6A7Z] [85]
Nefazodone DM4ZS8M Moderate Additive CNS depression effects by the combination of Thalidomide and Nefazodone. Depression [6A70-6A7Z] [85]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Thalidomide and Isocarboxazid. Depression [6A70-6A7Z] [85]
Escitalopram DMFK9HG Moderate Additive CNS depression effects by the combination of Thalidomide and Escitalopram. Depression [6A70-6A7Z] [85]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Thalidomide and Desvenlafaxine. Depression [6A70-6A7Z] [85]
OPC-34712 DMHG57U Moderate Additive CNS depression effects by the combination of Thalidomide and OPC-34712. Depression [6A70-6A7Z] [85]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Thalidomide and Clomipramine. Depression [6A70-6A7Z] [85]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Thalidomide and Doxepin. Depression [6A70-6A7Z] [85]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Thalidomide and Esketamine. Depression [6A70-6A7Z] [85]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [80]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Thalidomide and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [84]
Tetrabenazine DMYWQ0O Moderate Additive CNS depression effects by the combination of Thalidomide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [85]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Thalidomide and Deutetrabenazine. Dystonic disorder [8A02] [85]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Thalidomide and Ingrezza. Dystonic disorder [8A02] [85]
Methsuximide DM6L5VO Moderate Additive CNS depression effects by the combination of Thalidomide and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [85]
Cenobamate DMGOVHA Moderate Additive CNS depression effects by the combination of Thalidomide and Cenobamate. Epilepsy/seizure [8A61-8A6Z] [85]
Stiripentol DMMSDOY Moderate Additive CNS depression effects by the combination of Thalidomide and Stiripentol. Epilepsy/seizure [8A61-8A6Z] [85]
Phenacemide DMOHS9P Moderate Additive CNS depression effects by the combination of Thalidomide and Phenacemide. Epilepsy/seizure [8A61-8A6Z] [84]
Fosphenytoin DMOX3LB Moderate Additive CNS depression effects by the combination of Thalidomide and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [85]
Brivaracetam DMSEPK8 Moderate Additive CNS depression effects by the combination of Thalidomide and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [85]
Clonazepam DMTO13J Moderate Additive CNS depression effects by the combination of Thalidomide and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [85]
Lacosamide DMVM6QR Moderate Additive CNS depression effects by the combination of Thalidomide and Lacosamide. Epilepsy/seizure [8A61-8A6Z] [85]
Rufinamide DMWE60C Moderate Additive CNS depression effects by the combination of Thalidomide and Rufinamide. Epilepsy/seizure [8A61-8A6Z] [85]
Phenobarbital DMXZOCG Moderate Additive CNS depression effects by the combination of Thalidomide and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [85]
Vigabatrin DMYT0OG Moderate Additive CNS depression effects by the combination of Thalidomide and Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [85]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Thalidomide and Cannabidiol. Epileptic encephalopathy [8A62] [85]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Thalidomide and Diphenhydramine. Episodic vestibular syndrome [AB31] [85]
Nadolol DMW6GVL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Nadolol. Essential hypertension [BA00] [81]
Dantrolene DM1D8XY Moderate Additive CNS depression effects by the combination of Thalidomide and Dantrolene. Fever [MG26] [85]
Sunitinib DMCBJSR Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [81]
Metipranolol DMJMVKI Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Metipranolol. Glaucoma [9C61] [81]
Levobetaxolol DMSREPX Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levobetaxolol. Glaucoma [9C61] [81]
Levobunolol DMTNFCQ Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levobunolol. Glaucoma [9C61] [81]
Pilocarpine DMV9ADG Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pilocarpine. Glaucoma [9C61] [81]
Colchicine DM2POTE Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Colchicine. Gout [FA25] [80]
Carvedilol DMHTEAO Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Carvedilol. Heart failure [BD10-BD1Z] [81]
Digitoxin DMWVIGP Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Digitoxin. Heart failure [BD10-BD1Z] [81]
Telbivudine DMSWUGE Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Telbivudine. Hepatitis virus infection [1E50-1E51] [80]
Procarbazine DMIK367 Major Additive thrombogenic effects by the combination of Thalidomide and Procarbazine. Hodgkin lymphoma [2B30] [82]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [80]
Fostemsavir DM50ILT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [81]
Saquinavir DMG814N Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [81]
Etravirine DMGV8QU Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Etravirine. Human immunodeficiency virus disease [1C60-1C62] [80]
Lopinavir DMITQS0 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [81]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [81]
Atazanavir DMSYRBX Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Atazanavir. Human immunodeficiency virus disease [1C60-1C62] [81]
Fluvastatin DM4MDJY Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Fluvastatin. Hyper-lipoproteinaemia [5C80] [80]
Rosuvastatin DMMIQ7G Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [80]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Thalidomide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [87]
Penbutolol DM4ES8F Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Penbutolol. Hypertension [BA00-BA04] [81]
Nebivolol DM7F1PA Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Nebivolol. Hypertension [BA00-BA04] [81]
Levamlodipine DM92S6N Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levamlodipine. Hypertension [BA00-BA04] [81]
Hydralazine DMU8JGH Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Hydralazine. Hypertension [BA00-BA04] [80]
Clevidipine butyrate DMW4M97 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Clevidipine butyrate. Hypertension [BA00-BA04] [81]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Thalidomide and Suvorexant. Insomnia [7A00-7A0Z] [85]
Amobarbital DM0GQ8N Moderate Additive CNS depression effects by the combination of Thalidomide and Amobarbital. Insomnia [7A00-7A0Z] [84]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Thalidomide and Tasimelteon. Insomnia [7A00-7A0Z] [85]
Paraldehyde DMOC1BX Moderate Additive CNS depression effects by the combination of Thalidomide and Paraldehyde. Insomnia [7A00-7A0Z] [84]
ITI-007 DMUQ1DO Moderate Additive CNS depression effects by the combination of Thalidomide and ITI-007. Insomnia [7A00-7A0Z] [85]
Quazepam DMY4D87 Moderate Additive CNS depression effects by the combination of Thalidomide and Quazepam. Insomnia [7A00-7A0Z] [85]
Estazolam DMZGXUM Moderate Additive CNS depression effects by the combination of Thalidomide and Estazolam. Insomnia [7A00-7A0Z] [85]
Remimazolam DMLVSYX Moderate Additive CNS depression effects by the combination of Thalidomide and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [84]
Nelarabine DMB6VEG Major Additive thrombogenic effects by the combination of Thalidomide and Nelarabine. Leukaemia [2A60-2B33] [82]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Thalidomide and Denosumab. Low bone mass disorder [FB83] [88]
Crizotinib DM4F29C Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Crizotinib. Lung cancer [2C25] [81]
Ceritinib DMB920Z Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Ceritinib. Lung cancer [2C25] [81]
Lurbinectedin DMEFRTZ Major Additive thrombogenic effects by the combination of Thalidomide and Lurbinectedin. Lung cancer [2C25] [82]
Osimertinib DMRJLAT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Osimertinib. Lung cancer [2C25] [81]
Selpercatinib DMZR15V Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Selpercatinib. Lung cancer [2C25] [81]
Lumefantrine DM29GAD Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lumefantrine. Malaria [1F40-1F45] [81]
Halofantrine DMOMK1V Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Halofantrine. Malaria [1F40-1F45] [81]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Hydroxychloroquine. Malaria [1F40-1F45] [81]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [81]
Calaspargase pegol DMQZBXI Major Additive thrombogenic effects by the combination of Thalidomide and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [86]
Fludarabine DMVRLT7 Major Additive thrombogenic effects by the combination of Thalidomide and Fludarabine. Malignant haematopoietic neoplasm [2B33] [82]
Arsenic trioxide DM61TA4 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [81]
Ponatinib DMYGJQO Major Additive thrombogenic effects by the combination of Thalidomide and Ponatinib. Mature B-cell lymphoma [2A85] [82]
Arry-162 DM1P6FR Major Additive thrombogenic effects by the combination of Thalidomide and Arry-162. Melanoma [2C30] [82]
Vemurafenib DM62UG5 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Vemurafenib. Melanoma [2C30] [81]
LGX818 DMNQXV8 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and LGX818. Melanoma [2C30] [81]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Thalidomide and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [89]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Thalidomide and Lasmiditan. Migraine [8A80] [90]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Thalidomide and Flibanserin. Mood disorder [6A60-6E23] [91]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Thalidomide and Tecfidera. Multiple sclerosis [8A40] [92]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Thalidomide and Siponimod. Multiple sclerosis [8A40] [81]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Thalidomide and Fingolimod. Multiple sclerosis [8A40] [93]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Thalidomide and Ocrelizumab. Multiple sclerosis [8A40] [94]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Thalidomide and Ozanimod. Multiple sclerosis [8A40] [83]
Deflazacort DMV0RNS Major Additive thrombogenic effects by the combination of Thalidomide and Deflazacort. Muscular dystrophy [8C70] [82]
Neostigmine DM6T2J3 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Neostigmine. Myasthenia gravis [8C6Y] [81]
Ambenonium DMOP0BL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Ambenonium. Myasthenia gravis [8C6Y] [81]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Romidepsin. Mycosis fungoides [2B01] [81]
Vorinostat DMWMPD4 Major Additive thrombogenic effects by the combination of Thalidomide and Vorinostat. Mycosis fungoides [2B01] [82]
Decitabine DMQL8XJ Major Additive thrombogenic effects by the combination of Thalidomide and Decitabine. Myelodysplastic syndrome [2A37] [82]
Nilotinib DM7HXWT Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Nilotinib. Myeloproliferative neoplasm [2A20] [81]
Dasatinib DMJV2EK Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Dasatinib. Myeloproliferative neoplasm [2A20] [81]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Thalidomide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [95]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Thalidomide and Phenindamine. Nasopharyngitis [CA00] [84]
Promethazine DM6I5GR Moderate Additive CNS depression effects by the combination of Thalidomide and Promethazine. Nausea/vomiting [MD90] [85]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Thalidomide and Cyclizine. Nausea/vomiting [MD90] [84]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Thalidomide and Metoclopramide. Nausea/vomiting [MD90] [85]
E-2007 DMJDYNQ Moderate Additive CNS depression effects by the combination of Thalidomide and E-2007. Neuropathy [8C0Z] [85]
Entrectinib DMMPTLH Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Entrectinib. Non-small cell lung cancer [2C25] [81]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Thalidomide and Sibutramine. Obesity [5B80-5B81] [84]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Thalidomide and Levomethadyl Acetate. Opioid use disorder [6C43] [83]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Thalidomide and Lofexidine. Opioid use disorder [6C43] [85]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Rucaparib. Ovarian cancer [2C73] [81]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Thalidomide and Oxymorphone. Pain [MG30-MG3Z] [85]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Thalidomide and Dezocine. Pain [MG30-MG3Z] [84]
Flavoxate DMKV4NL Moderate Additive CNS depression effects by the combination of Thalidomide and Flavoxate. Pain [MG30-MG3Z] [85]
Ziconotide DMSLJP4 Moderate Additive CNS depression effects by the combination of Thalidomide and Ziconotide. Pain [MG30-MG3Z] [85]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Triclabendazole. Parasitic worm infestation [1F90] [81]
Pergolide DM14MAE Moderate Additive CNS depression effects by the combination of Thalidomide and Pergolide. Parkinsonism [8A00] [85]
Opicapone DM1BKA6 Moderate Additive CNS depression effects by the combination of Thalidomide and Opicapone. Parkinsonism [8A00] [84]
Rasagiline DM3WKQ4 Moderate Additive CNS depression effects by the combination of Thalidomide and Rasagiline. Parkinsonism [8A00] [85]
Levodopa DMN3E57 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Levodopa. Parkinsonism [8A00] [80]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pimavanserin. Parkinsonism [8A00] [81]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Thalidomide and Bromocriptine. Parkinsonism [8A00] [85]
Orphenadrine DMW542E Moderate Additive CNS depression effects by the combination of Thalidomide and Orphenadrine. Parkinsonism [8A00] [85]
Macimorelin DMQYJIR Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Macimorelin. Pituitary gland disorder [5A60-5A61] [81]
Lefamulin DME6G97 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lefamulin. Pneumonia [CA40] [81]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Degarelix. Prostate cancer [2C82] [81]
ABIRATERONE DM8V75C Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and ABIRATERONE. Prostate cancer [2C82] [81]
Enzalutamide DMGL19D Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Enzalutamide. Prostate cancer [2C82] [81]
Relugolix DMK7IWL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Relugolix. Prostate cancer [2C82] [81]
Estramustine DMWTAOI Major Additive thrombogenic effects by the combination of Thalidomide and Estramustine. Prostate cancer [2C82] [86]
Bicalutamide DMZMSPF Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Bicalutamide. Prostate cancer [2C82] [81]
Terazosin DM3JCVS Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Terazosin. Prostate hyperplasia [GA90] [81]
Levomepromazine DMIKFEL Moderate Additive CNS depression effects by the combination of Thalidomide and Levomepromazine. Psychotic disorder [6A20-6A25] [83]
Axitinib DMGVH6N Major Additive thrombogenic effects by the combination of Thalidomide and Axitinib. Renal cell carcinoma [2C90] [82]
Gatifloxacin DMSL679 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [81]
Neupro DMHEAB1 Moderate Additive CNS depression effects by the combination of Thalidomide and Neupro. Restless legs syndrome [7A80] [85]
Tocilizumab DM7J6OR Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Tocilizumab. Rheumatoid arthritis [FA20] [80]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Thalidomide and Canakinumab. Rheumatoid arthritis [FA20] [96]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Thalidomide and Rilonacept. Rheumatoid arthritis [FA20] [96]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Thalidomide and Golimumab. Rheumatoid arthritis [FA20] [97]
Dexamethasone DMMWZET Major Additive thrombogenic effects by the combination of Thalidomide and Dexamethasone. Rheumatoid arthritis [FA20] [82]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Thalidomide and Leflunomide. Rheumatoid arthritis [FA20] [87]
Quetiapine DM1N62C Moderate Additive CNS depression effects by the combination of Thalidomide and Quetiapine. Schizophrenia [6A20] [85]
Aripiprazole DM3NUMH Moderate Additive CNS depression effects by the combination of Thalidomide and Aripiprazole. Schizophrenia [6A20] [85]
Iloperidone DM6AUFY Moderate Additive CNS depression effects by the combination of Thalidomide and Iloperidone. Schizophrenia [6A20] [85]
Paliperidone DM7NPJS Moderate Additive CNS depression effects by the combination of Thalidomide and Paliperidone. Schizophrenia [6A20] [85]
Molindone DMAH70G Moderate Additive CNS depression effects by the combination of Thalidomide and Molindone. Schizophrenia [6A20] [85]
Thiothixene DMDINC4 Moderate Additive CNS depression effects by the combination of Thalidomide and Thiothixene. Schizophrenia [6A20] [85]
Amisulpride DMSJVAM Moderate Additive CNS depression effects by the combination of Thalidomide and Amisulpride. Schizophrenia [6A20] [85]
Asenapine DMSQZE2 Moderate Additive CNS depression effects by the combination of Thalidomide and Asenapine. Schizophrenia [6A20] [85]
Pimozide DMW83TP Moderate Additive CNS depression effects by the combination of Thalidomide and Pimozide. Schizophrenia [6A20] [85]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Thalidomide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [98]
Ifosfamide DMCT3I8 Major Additive thrombogenic effects by the combination of Thalidomide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [82]
Docetaxel DMDI269 Major Additive thrombogenic effects by the combination of Thalidomide and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [82]
Trabectedin DMG3Y89 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [80]
Mitoxantrone DMM39BF Major Additive thrombogenic effects by the combination of Thalidomide and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [82]
LEE011 DMMX75K Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and LEE011. Solid tumour/cancer [2A00-2F9Z] [81]
Vandetanib DMRICNP Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [81]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [81]
Taxol DMUOT9V Major Additive thrombogenic effects by the combination of Thalidomide and Taxol. Solid tumour/cancer [2A00-2F9Z] [82]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pitolisant. Somnolence [MG42] [81]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [81]
Plicamycin DM7C8YV Major Additive thrombogenic effects by the combination of Thalidomide and Plicamycin. Testicular cancer [2C80] [86]
Lenvatinib DMB1IU4 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lenvatinib. Thyroid cancer [2D10] [81]
Cabozantinib DMIYDT4 Major Additive thrombogenic effects by the combination of Thalidomide and Cabozantinib. Thyroid cancer [2D10] [82]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Thalidomide and Papaverine. Tonus and reflex abnormality [MB47] [99]
Secnidazole DMJ18YL Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Secnidazole. Vaginal discharge [MF3A] [80]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Thalidomide and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [85]
Trimeprazine DMEMV9D Moderate Additive CNS depression effects by the combination of Thalidomide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [83]
Propafenone DMPIBJK Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Propafenone. Ventricular tachyarrhythmia [BC71] [81]
Flecainide DMSQDLE Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Flecainide. Ventricular tachyarrhythmia [BC71] [81]
Amiodarone DMUTEX3 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Amiodarone. Ventricular tachyarrhythmia [BC71] [81]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Thalidomide and Valganciclovir. Virus infection [1A24-1D9Z] [81]
⏷ Show the Full List of 215 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Magnesium stearate E00208 11177 lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Thalidomide 100 mg capsule 100 mg Oral Capsule Oral
Thalidomide 150 mg capsule 150 mg Oral Capsule Oral
Thalidomide 200 mg capsule 200 mg Oral Capsule Oral
Thalidomide 50 mg capsule 50 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7327).
2 Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):973-85.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
7 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8 Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
9 Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
10 Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
11 Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem Res Toxicol. 2010 Jun 21;23(6):1018-24.
12 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
17 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
18 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
19 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
20 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
21 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
22 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
23 Drug Interactions Flockhart Table
24 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
25 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
26 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
28 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
29 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
30 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
31 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
32 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
33 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
34 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
35 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
36 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
37 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
38 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
39 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
40 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
41 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
42 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
43 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
44 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
45 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
46 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
47 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
48 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
49 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
50 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
51 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
52 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
53 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
54 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
55 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
56 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
57 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
58 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
59 Drugs that may have potential CYP2B6 interactions.
60 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
61 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
62 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
63 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
64 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
65 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
66 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
67 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
68 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
69 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
70 Clinical pipeline report, company report or official report of AstraZeneca (2009).
71 Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
72 Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
73 Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
74 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
75 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
76 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
77 Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
78 Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
79 TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
80 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
81 Cerner Multum, Inc. "Australian Product Information.".
82 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
83 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
84 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
85 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
86 Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
87 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
88 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
89 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
90 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
91 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
92 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
93 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
94 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
95 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
96 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
97 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
98 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
99 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]